Enrollment has been completed in Genentech’s phase 2 clinical trial of the ranibizumab port delivery system implant in patients with wet age-related macular degeneration, according to a company announcement.
The multicenter, randomized, active treatment-controlled LADDER (Long Acting Delivery of Ranibizumab) trial is evaluating the efficacy of the RPDS implant for the sustained delivery of Lucentis in patients with wet AMD who have previously responded to anti-VEGF treatment.
The trial is evaluating the implant with three different ranibizumab formulations. “The primary endpoint is
Uncategorized